Canada
['MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone', 'Puerto Rico', 'Canada', 'A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis', 65, 'clinical trial']